Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × Lapatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 62 Neoplasm Metastasis 12 Neoplasms 8 Breast Neoplasms, Male 7 Ovarian Neoplasms 4 Brain Neoplasms 4 Carcinoma, Squamous Cell 3 Urinary Bladder Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumors 2 Neuroma, Acoustic 2 Neurofibromatosis 2 2 Inflammatory Breast Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Ductal, Breast 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Patient Compliance 1 Pancreatic Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neurilemmoma 1 Neoplastic Cells, Circulating 1 Metastatic Breast Cancer With Intracranial Metastases 1 Lung Neoplasms 1 HER2-positive Refractory Advanced Cancer 1

Interventions

Docetaxel 147 Magnetic Resonance Spectroscopy 122 Radiotherapy 121 Leuprolide 97 Prednisone 94 enzalutamide 90 Radiosurgery 89 Abiraterone Acetate 78 Androgen Antagonists 77 Goserelin 71 bicalutamide 68 gallium 68 PSMA-11 56 Specimen Handling 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 50 Surveys and Questionnaires 50 apalutamide 48 Radiation 42 Biopsy 42 Brachytherapy 39 Gonadotropin-Releasing Hormone 38 Standard of Care 37 abiraterone 35 Blood Specimen Collection 34 darolutamide 33 cabazitaxel 33 Radiotherapy, Intensity-Modulated 32 Exercise 32 Carboplatin 31 Triptorelin Pamoate 28 Pluvicto 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00246753 2017-06-28

NRR

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed

29 enrolled 8 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡